Education
About Us
Working with TipRanks
Follow Us
Edesa Biotech (EDSA)
:EDSA
EDSA Stock Chart & Stats
$2.51
>-$0.01(-0.02%)
At close: 4:00 PM EST
$2.51
>-$0.01(-0.02%)
Day’s Range― - ―
52-Week Range$1.55 - $4.49
Previous CloseN/A
Volume1.31K
Average Volume (3M)92.14K
Market Cap
$17.86M
Enterprise Value$11.12M
Total Cash (Recent Filing)$12.36M
Total Debt (Recent Filing)$0.00
Price to Earnings (P/E)―
Beta0.78
Next Earnings
Dec 12, 2025EPS Estimate
-0.26Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.25
Shares Outstanding7,037,648
10 Day Avg. Volume241,502
30 Day Avg. Volume92,139
Financial Highlights & Ratios
PEG Ratio0.07
Price to Book (P/B)7.18
Price to Sales (P/S)0.00
P/FCF Ratio-2.91
Enterprise Value/Market Cap0.62
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-119.02
Enterprise Value/Ebitda-1.91
Forecast
1Y Price Target
$5.00Price Target Upside99.20% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering0
Bulls Say, Bears Say
Bulls Say
Analyst RatingAnalyst assumes coverage of Edesa with a Buy rating and a 12-month price target of $5.
Drug DevelopmentThe lead drug candidate, EB06, has shown favorable safety and tolerability profiles in prior Phase 1 trials.
Regulatory ApprovalHealth Canada has approved Edesa Biotech to conduct a Phase 2 trial of EB06 in moderate to severe nonsegmental vitiligo patients.
Bears Say
Edesa Biotech News
EDSA FAQ
What was Edesa Biotech’s price range in the past 12 months?
Edesa Biotech lowest stock price was $1.55 and its highest was $4.49 in the past 12 months.
What is Edesa Biotech’s market cap?
Edesa Biotech’s market cap is $17.86M.
When is Edesa Biotech’s upcoming earnings report date?
Edesa Biotech’s upcoming earnings report date is Dec 12, 2025 which is in 58 days.
How were Edesa Biotech’s earnings last quarter?
Edesa Biotech released its earnings results on Aug 08, 2025. The company reported -$0.25 earnings per share for the quarter, beating the consensus estimate of -$0.263 by $0.013.
Is Edesa Biotech overvalued?
According to Wall Street analysts Edesa Biotech’s price is currently Undervalued.
Does Edesa Biotech pay dividends?
Edesa Biotech does not currently pay dividends.
What is Edesa Biotech’s EPS estimate?
Edesa Biotech’s EPS estimate is -0.26.
How many shares outstanding does Edesa Biotech have?
Edesa Biotech has 7,037,648 shares outstanding.
What happened to Edesa Biotech’s price movement after its last earnings report?
Edesa Biotech reported an EPS of -$0.25 in its last earnings report, beating expectations of -$0.263. Following the earnings report the stock price went down -0.472%.
Which hedge fund is a major shareholder of Edesa Biotech?
Currently, no hedge funds are holding shares in EDSA
Company Description
Edesa Biotech
Edesa Biotech (EDSA) is a clinical-stage biopharmaceutical company that focuses on the development of innovative treatments for inflammatory and immune-related diseases. Operating primarily in the biotechnology sector, the company aims to address unmet medical needs by advancing its pipeline of novel drug candidates. Edesa Biotech's core products include monoclonal antibodies and other biologics designed to modulate the immune response and provide therapeutic solutions for conditions such as allergic and inflammatory diseases.
Technical Analysis
Eterna Therapeutics
―
Lipocine
―
XTL Biopharmaceuticals Sponsored ADR
―
Cocrystal Pharma
―
BioVie
―
Ownership Overview
19.22% Insiders
0.55% Mutual Funds
28.42% Other Institutional Investors
51.35% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---